These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 2462341)

  • 1. Classification of deaths after myocardial infarction as arrhythmic or nonarrhythmic (the Cardiac Arrhythmia Pilot Study).
    Greene HL; Richardson DW; Barker AH; Roden DM; Capone RJ; Echt DS; Friedman LM; Gillespie MJ; Hallstrom AP; Verter J
    Am J Cardiol; 1989 Jan; 63(1):1-6. PubMed ID: 2462341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recruitment and baseline description of patients in the Cardiac Arrhythmia Pilot Study. The Cardiac Arrhythmia Pilot Study (CAPS) investigators.
    Am J Cardiol; 1988 Apr; 61(10):704-13. PubMed ID: 2451414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS.
    Cardiac Arrhythmia Pilot Study (CAPS) Investigators
    Am J Cardiol; 1988 Mar; 61(8):501-9. PubMed ID: 2894169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
    Cardiac Arrhythmia Suppression Trial (CAST) Investigators
    N Engl J Med; 1989 Aug; 321(6):406-12. PubMed ID: 2473403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circadian pattern of arrhythmic death in patients receiving encainide, flecainide or moricizine in the Cardiac Arrhythmia Suppression Trial (CAST).
    Peters RW; Mitchell LB; Brooks MM; Echt DS; Barker AH; Capone R; Liebson PR; Greene HL
    J Am Coll Cardiol; 1994 Feb; 23(2):283-9. PubMed ID: 8294678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST).
    Anderson JL; Platia EV; Hallstrom A; Henthorn RW; Buckingham TA; Carlson MD; Carson PE
    Circulation; 1994 Dec; 90(6):2843-52. PubMed ID: 7994829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Congestive heart failure after acute myocardial infarction in patients receiving antiarrhythmic agents for ventricular premature complexes (Cardiac Arrhythmia Pilot Study).
    Greene HL; Richardson DW; Hallstrom AP; McBride R; Capone RJ; Barker AH; Roden DM; Echt DS
    Am J Cardiol; 1989 Feb; 63(7):393-8. PubMed ID: 2464919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
    Echt DS; Liebson PR; Mitchell LB; Peters RW; Obias-Manno D; Barker AH; Arensberg D; Baker A; Friedman L; Greene HL
    N Engl J Med; 1991 Mar; 324(12):781-8. PubMed ID: 1900101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST).
    Epstein AE; Hallstrom AP; Rogers WJ; Liebson PR; Seals AA; Anderson JL; Cohen JD; Capone RJ; Wyse DG
    JAMA; 1993 Nov; 270(20):2451-5. PubMed ID: 8230622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time to arrhythmic, ischemic, and heart failure events: exploratory analyses to elucidate mechanisms of adverse drug effects in the Cardiac Arrhythmia Suppression Trial.
    Hallstrom AP; Anderson JL; Carlson M; Davies R; Greene HL; Kammerling JM; Romhilt DW; Duff HJ; Huther M
    Am Heart J; 1995 Jul; 130(1):71-9. PubMed ID: 7611126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial. CAST Investigators.
    Akiyama T; Pawitan Y; Greenberg H; Kuo CS; Reynolds-Haertle RA
    Am J Cardiol; 1991 Dec; 68(17):1551-5. PubMed ID: 1720917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Location of death (in-hospital or out-of-hospital) and type of death (arrhythmic, nonarrhythmic, noncardiac) after inducible sustained ventricular tachyarrhythmias after syncope, sustained ventricular tachycardia, or nonfatal cardiac arrest (the ESVEM trial).
    Olshansky B; Hartz V; Hahn E; Mason J; Weaver MD;
    Am J Cardiol; 2000 Oct; 86(8):846-51. PubMed ID: 11024399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relation of baseline characteristics to suppression of ventricular arrhythmias during placebo and active antiarrhythmic therapy in patients after myocardial infarction.
    Anderson JL; Hallstrom AP; Griffith LS; Ledingham RB; Reiffel JA; Yusuf S; Barker AH; Fowles RE; Young JB
    Circulation; 1989 Mar; 79(3):610-9. PubMed ID: 2465099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Events in the cardiac arrhythmia suppression trial: baseline predictors of mortality in placebo-treated patients.
    Capone RJ; Pawitan Y; el-Sherif N; Geraci TS; Handshaw K; Morganroth J; Schlant RC; Waldo AL
    J Am Coll Cardiol; 1991 Nov; 18(6):1434-8. PubMed ID: 1939943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting mortality after myocardial infarction from the response of RR variability to antiarrhythmic drug therapy.
    Bigger JT; Rolnitzky LM; Steinman RC; Fleiss JL
    J Am Coll Cardiol; 1994 Mar; 23(3):733-40. PubMed ID: 7509355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in the entire population enrolled.
    Epstein AE; Bigger JT; Wyse DG; Romhilt DW; Reynolds-Haertle RA; Hallstrom AP
    J Am Coll Cardiol; 1991 Jul; 18(1):14-9. PubMed ID: 1904891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinction between arrhythmic and nonarrhythmic death after acute myocardial infarction based on heart rate variability, signal-averaged electrocardiogram, ventricular arrhythmias and left ventricular ejection fraction.
    Hartikainen JE; Malik M; Staunton A; Poloniecki J; Camm AJ
    J Am Coll Cardiol; 1996 Aug; 28(2):296-304. PubMed ID: 8800101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of ischaemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST I.
    Greenberg HM; Dwyer EM; Hochman JS; Steinberg JS; Echt DS; Peters RW
    Br Heart J; 1995 Dec; 74(6):631-5. PubMed ID: 8541168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of ventricular premature depolarizations measured 1 year after myocardial infarction in patients with early postinfarction asymptomatic ventricular arrhythmia.
    Hallstrom AP; Bigger JT; Roden D; Friedman L; Akiyama T; Richardson DW; Rogers WJ; Waldo AL; Pratt CM; Capone RJ
    J Am Coll Cardiol; 1992 Aug; 20(2):259-64. PubMed ID: 1378858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Cardiac Arrhythmia Suppression Trial: background, interim results and implications.
    Pratt CM; Moye LA
    Am J Cardiol; 1990 Jan; 65(4):20B-29B. PubMed ID: 2105049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.